All Over But The Lawsuits? NCE Exclusivity For Fixed-Dose Combos Remains Prospective

FDA rejects requests by firms to make new policy retroactive; Gilead’s Harvoni and Eisai’s Akynzeo fixed combos, approved the day FDA issued its final guidance, granted exclusivity.